Position in SVTR
Snapshot 2026-10-25- Startup SignalsRankedof 2,336↓61
- Life SciencesRankedof 247↓5
- Drug DiscoveryRankedof 58↓2
- AssistantRankedof 52↓4
About
Cheiron , a two-year-old startup based in Los Altos, CA, that helps biopharma teams map the evidence, assumptions, risks, decisions, and regulatory context behind drug development programs, raised an $8 million seed round led by Menlo Ventures, with Robert Langer, Freda Lewis-Hall, Josh Meier, Laxman Narasimhan , and John Giannandrea also participating.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-07-22Seed$8M
Investors · Menlo Ventures, Josh MeierSource · cheiron.bio ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Cheiron
AI-native "drug program operating system" for biopharma teams that models drug R&D programs on a life sciences knowledge graph
Seed · $8M · 2026-07
$8M
United States
BusinessLatest roundTotal raisedDate- Argon AI
Digital collaboration platform with integrated AI tools for biopharma teams to manage research projects and data
Seed · $6M · 2025-07
$6M - Katalyze AI
Agentic AI operating system for pharmaceutical manufacturing
Seed · $11M · 2026-07
$11M - QbDVision
Digital CMC platform for pharma and biotech companies, streamlining drug development through structured workflows
Undisclosed · $13M · 2025-05
$13M
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - ATLATL Innovation Center
ATLATL is a life-science innovation and shared-lab operator founded in 2017 in Shanghai's Zhangjiang, providing move-in-ready labs, on-site CRO services and R&D platforms (gene and cell therapy, AI-assisted drug screening, large-molecule research) to early-stage biotech companies across Shanghai, Beijing, Shenzhen, Hong Kong, Singapore and Australia.
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M
Europe
BusinessLatest roundTotal raisedDate- Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - kyron.bio
Develops a precision biotech platform for engineering glycans to improve drug efficacy and safety
Seed · $6M · 2025-05
$6M - DaltonTx
Adaptive AI discovery platform for drug development
Seed · $6M · 2025-09
$6M
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Congruence
Computation-driven drugs for genetic diseases (including CGX-926)
Undisclosed · $32M · 2025-09
$32M - Altis Labs
AI imaging biomarker platform across solid tumor types and therapeutic areas
Series A · $31M · 2026-09
$31M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 19 at a nearby stage · 36 in Silicon Valley
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 31 in Silicon Valley
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 22 in Silicon Valley
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in Silicon Valley
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in Silicon Valley
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 5 at a nearby stage · 15 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.